Cargando…
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Anaplastic lymphoma kinase (ALK) translocations are responsible of neoplastic transformation in a limited subset of non-small cell lung cancer (NSCLC) patients. In recent years outcomes of these patients improved due to the development and clinical availability of specific and extremely active targe...
Autores principales: | Tabbò, Fabrizio, Reale, Maria Lucia, Bironzo, Paolo, Scagliotti, Giorgio V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815358/ https://www.ncbi.nlm.nih.gov/pubmed/33489817 http://dx.doi.org/10.21037/tlcr-20-372 |
Ejemplares similares
-
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
por: Bersani, Francesca, et al.
Publicado: (2020) -
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020) -
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
por: Passiglia, Francesco, et al.
Publicado: (2020) -
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020) -
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)